Europe's medicines ‌regulator ‌on Friday recommended ​granting marketing authorisation to mCombriax, ‌making ⁠Moderna's messenger RNA vaccine ⁠the world's ​first ​combined ​shot for ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 ...

Since being sworn in as Health and Human Services (HHS) secretary, Robert F. Kennedy Jr has repeatedly tried to undermine public trust in vaccines. His agency recently took steps to slow down the ...

The Food and Drug Administration refused to review Moderna’s application for its new mRNA flu vaccine — a move the pharma giant’s’s president Dr. Stephen Hoge said left him in “complete shock.” In an ...

The stock’s movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license ...

The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on ...

Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials. In 2025, Moderna spent $3.1 billion on ...

The Food and Drug Administration on Wednesday defended its rejection of Moderna’s mRNA-based flu vaccine application, saying the company’s clinical trial design put patients at risk. The FDA’s defense ...

NEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe ...

Update: The FDA reversed its decision on Feb. 18 and agreed to consider Moderna's application. Read the latest here. Our earlier story is below. The Food and Drug Administration is refusing to ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year. Recordati, an Italian company that ...